Top Markets
Coin of the day
TaiwanJ Pharmaceuticals Co., Ltd. TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd.

6549
Rank in Stocks #30200
TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm... TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm dedicated to the research, development, and commercialization of small molecule therapeutics. Initially, its focus within Taiwan has been on tackling chronic organ inflammation stemming from metabolic, autoimmune, or infectious causes. The company's growing pipeline also features specific compounds like JKB-122 and JKB-121, alongside a collection of innovative chemical entities. These new drugs are being developed to address persistent liver conditions and allergic respiratory ailments, such as asthma. TaiwanJ's comprehensive product portfolio is engineered to combat a wide array of diseases, encompassing hepatic inflammation and fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), various autoimmune disorders, asthma, and atopic dermatitis (eczema). Established in 2011, the company's operations are headquartered in Zhubei, Taiwan.
Share Price
$0.22227521
Market Cap
$17.81M
Change (1 day)
0.00%
Change (1 year)
-14.81%
Country
TW
Trade TaiwanJ Pharmaceuticals Co., Ltd. (6549)

Category

P/B ratio for TaiwanJ Pharmaceuticals Co., Ltd. (6549)
P/B ratio as of 2026 TTM: 0
According to TaiwanJ Pharmaceuticals Co., Ltd. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for TaiwanJ Pharmaceuticals Co., Ltd. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR